905403-96-5 Usage
Benzimidazole derivative
A heterocyclic compound with a fused benzene and imidazole ring This compound is derived from benzimidazole, which is a heterocyclic compound formed by the fusion of a benzene ring and an imidazole ring.
Carboxylic acid
Contains a carboxyl functional group (COOH) This indicates that the compound has a carboxyl group, which is a functional group consisting of a carbonyl group (C=O) and a hydroxyl group (OH) connected to the same carbon atom.
Methoxyphenyl group
Substitution of a methoxy (CH3O-) group on the phenyl ring The presence of a methoxy group in the compound suggests that it is substituted on the phenyl ring, which may influence its chemical properties and potential applications.
Potential applications in pharmaceuticals
Known for various biological activities, including antimicrobial, antiviral, and antitumor properties As a benzimidazole derivative, this compound may have potential applications in the pharmaceutical industry due to its known biological activities.
Further research needed
To reveal specific uses and potential benefits of 2-(3-Methoxyphenyl)-1H-benzimidazole-5-carboxylic acid While the compound has shown promise in possessing various biological activities, more research is needed to determine its specific uses and potential benefits in various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 905403-96-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,5,4,0 and 3 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 905403-96:
(8*9)+(7*0)+(6*5)+(5*4)+(4*0)+(3*3)+(2*9)+(1*6)=155
155 % 10 = 5
So 905403-96-5 is a valid CAS Registry Number.
905403-96-5Relevant articles and documents
Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives
Cong, Chao,Wang, Haiyang,Hu, Yue,Liu, Chen,Ma, Siti,Li, Xin,Cao, Jichao,Ma, Shutao
, p. 3105 - 3111 (2011)
Novel 4″-O-benzimidazolyl clarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activities. These benzimidazolyl derivatives exhibited excellent activity against erythromycin-susceptible strains better than the references, and some of them showed greatly improved activity against erythromycin-resistant strains. Compounds 16 and 17, which have the terminal 2-(4-methylphenyl)benzimidazolyl and 2-(2-methoxyphenyl)benzimidazolyl groups on the C-4″ bishydrazide side chains, were the most active against erythromycin-resistant Staphylococcus pneumoniae expressing the erm gene and the mef gene. In addition, compound 17 exhibited the highest activity against erythromycin-susceptible S. pneumoniae ATCC49619 and Staphylococcus aureus ATCC25923 as well. It is worth noting that the 4″-O-(2-aryl)benzimidazolyl derivatives show higher activity against erythromycin-susceptible and erythromycin-resistant strains than the 4″-O-(2-alkyl)benzimidazolyl derivatives.
